Question 1

What is Neurimmune?

Accepted Answer

Neurimmune is a Entity.

Question 2

How often does Neurimmune appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 13 articles.

Question 3

When was Neurimmune first tracked by Ergen?

Accepted Answer

First tracked on Jun 24, 2026.

Question 4

When was Neurimmune last mentioned in news?

Accepted Answer

Last active on Jul 22, 2026.

Question 5

What is Neurimmune's current news sentiment?

Accepted Answer

Aggregate sentiment score: 15 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Neurimmune in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Neurimmune?

Accepted Answer

Royalty Pharma acquires Neurimmune royalty (Jul 22, 2026, 7 articles).

Question 8

How did the "Royalty Pharma acquires Neurimmune royalty" event impact Neurimmune?

Accepted Answer

Neurimmune receives up to $425 million in exchange for a portion of its royalty interest, providing funds to advance its R&D pipeline while retaining majority royalty and milestone interests.

Question 9

How did the "AL-S Pharma AP-101 Phase 2 Success" event impact Neurimmune?

Accepted Answer

Neurimmune is a co-owner of ALS Pharma, contributing to the development of IBM System/4 Pi.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.